Bioventus Inc
NASDAQ:BVS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.96
13.71
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Wall Street
Price Targets
BVS Price Targets Summary
Bioventus Inc
According to Wall Street analysts, the average 1-year price target for BVS is 15.3 USD with a low forecast of 13.13 USD and a high forecast of 17.85 USD.
BVS Last Price Targets
Bioventus Inc
The latest public price target was made on Oct 1, 2024 by
Caitlin Cronin
from
Canaccord Genuity
,
who expects
BVS
stock to
rise by 22%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Caitlin Cronin
Canaccord Genuity
|
12
USD
Upside 22% |
3 months ago
Oct 1, 2024
|
Canaccord Genuity Reiterates Buy Rating on Bioventus Inc (BVS)
StreetInsider
|
|
Chase Knickerbocker
Craig-Hallum
|
12
USD
Upside 22% |
5 months ago
Aug 7, 2024
|
Bioventus price target raised to $12 from $9 at Craig-Hallum
TheFly
|
|
William Plovanic
Canaccord Genuity
|
8
USD
Downside 19% |
8 months ago
May 7, 2024
|
Bioventus Inc (BVS) PT Raised to $8 at Canaccord Genuity
StreetInsider
|
|
Alex Nowak
Craig-Hallum
|
9
USD
Downside 8% |
9 months ago
Mar 13, 2024
|
Bioventus Inc (BVS) PT Raised to $9 at Craig-Hallum
StreetInsider
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is BVS's stock price target?
Price Target
15.3
USD
According to Wall Street analysts, the average 1-year price target for BVS is 15.3 USD with a low forecast of 13.13 USD and a high forecast of 17.85 USD.
What is Bioventus Inc's Revenue forecast?
Projected CAGR
8%
For the last 8 years the compound annual growth rate for Bioventus Inc's revenue is 9%. The projected CAGR for the next 3 years is 8%.
What is Bioventus Inc's Operating Income forecast?
Projected CAGR
346%
The compound annual growth rate of Bioventus Inc's operating income for the next 3 years is 346%.
You don't have any saved screeners yet
